Heparinoid (factor Xa inhibitor)

Danaparoid sodium

Brand names: Orgaran

Adult dose

Dose: Per HIT protocol — typically 2,250 units IV bolus then variable infusion

Route: IV / SC

Frequency: Variable

Clinical pearls

BSH HIT guideline: alternative to argatroban when fondaparinux/argatroban unsuitable
No specific antidote; supportive treatment + factor concentrates if severe bleed
UK supply now limited — argatroban / fondaparinux usually preferred

Contraindications

Active major bleeding
Severe renal impairment
Hypersensitivity to sulfites
Confirmed cross-reactivity (HIT antibody positive on testing)

Side effects

Bleeding
Cross-reactivity with HIT antibodies (~10%)
Injection-site reactions
Hypersensitivity

Interactions

Anticoagulants/antiplatelets

Monitoring

Anti-Xa (target 0.5–0.8 units/mL)
FBC
Renal function
Bleeding

Reference: BNF; BSH HIT guideline; https://bnf.nice.org.uk/drugs/danaparoid-sodium/. Verify against your local formulary and the latest BNF before prescribing.

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways